Dyne Therapeutics
Carlo has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. Carlo is currently an operating partner at Forbion, a life sciences venture capital firm. Previously, he held several positions of increasing responsibility during his more than 25 years at Sanofi Genzyme, including senior vice president, chief medical officer, and head of global medical affairs. He also served as senior vice president of global market access and held various roles at Genzyme’s European headquarters. He is chairman of the Board at Inversago Pharma, EryDel SpA, Azafaros B.V., VectorY Therapeutics, and a member of the Board of Numab Therapeutics AG. Carlo is also a founding member of the International Rare Diseases Research Consortium.
He received his medical degree from the University of Modena and Reggio Emilia, Italy.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Dyne Therapeutics
3 followers
Dyne is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases.